Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Rebecca Panks

  • Home
  • Author: Rebecca Panks

Jagged reopening of nations worldwide paves uncertain path to economic recovery, says GlobalData

As economies reopen globally, there is a constant battle to achieve a balance between surging COVID-19 cases and addressing economic slowdown. Due to the prevailing uncertainty following COVID-19, GlobalData’s 2020 forecast for global economic growth has been revised downward from -0.9% (estimated 6 April) to -3.95% (estimated 3 August). The signs of a faltering rebound […]
Read more

Fidelis Underwriting may have advantage over other insurers in UK sector, which risks drop in profitability due to huge reliance on life products, says GlobalData

The leading UK insurers are heavily reliant on the life sector, even compared to other European countries that have strong life leanings. Of the top ten companies, only Fidelis Underwriting was non-life, which could put it at a strong position, according to GlobalData, a leading data and analytics company.  Nine of the leading ten insurers […]
Read more

ResMed benefits from rising ventilator market, which sees forecast upwards adjustment of $3.8bn, says GlobalData

Following ResMed’s fiscal fourth quarter revenue report: Kamilla Kan, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view on the recent news: “ResMed’s year-over-year increase of 9% in revenue is largely due to the increase in sales and production of ventilators due to COVID-19. COVID-19 has had a profound effect […]
Read more

Russia’s lack of Phase III data for COVID-19 vaccine leaves some unconvinced of safety and efficacy, says GlobalData

Following the news that Russia has approved the first COVID-19 vaccine; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “The available clinical trial data for Russia’s COVID-19 vaccine, comprising 38 trial participants that have been followed for two months, is simply not enough to convince […]
Read more

AstraZeneca continues to take strategic steps towards differentiating Forxiga from SGLT-2 inhibitor competitors, says GlobalData

AstraZeneca’s Farxiga (dapagliflozin) is expected to significantly strengthen its presence in the the sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class of the cardiovascular and metabolic arena after recent findings suggested the drug can both reduce cardiovascular (CV) risk and decrease the risk of new-onset diabetes in HF-REF patients. Key opinion leaders (KOLs) interviewed by GlobalData have expressed […]
Read more

Growing UK offshore wind becomes cheaper than nuclear and gas, expanding installations that might help the nation accomplish 2030 target, says GlobalData

The Imperial College London conducted a study where it shows that the UK offshore wind generation costs have significantly declined in the last few years, tossing in the plausibility of the segment soon being subsidy negative as per their contract for difference (CfD). GlobalData anticipates that the declining costs not only make offshore wind a […]
Read more

Ireland’s renewable auction sees cost reduction and favourable mechanism to support country achieve decade-end target, says GloblaData

The first Renewable Energy Support Scheme (RESS-1) round of Ireland’s first green energy auction provided a stage for the rapid deployment of onshore wind and solar projects. GlobalData, a leading data and analytics company, predicts that the scheme will be pivotal to Ireland’s contribution towards the EU-wide renewable energy target of 32% of overall generation […]
Read more

Continued collection of longitudinal data suggested to assess immune response that COVID-19 triggers in pregnant women, says GlobalData

Recent study findings from the US Centers for Disease Control and Prevention (CDC) suggest there may be a difference in disease severity when comparing pregnant and nonpregnant women with COVID-19. Understanding the outcomes of pregnancy in COVID-19-positive women could prevent adverse outcomes on a large scale, and more data collection on pregnant women with COVID-19 […]
Read more

Although Lilly’s monoclonal antibody could be efficacious against COVID-19, recruitment could be slow, says GlobalData

Following the news of Eli Lilly and Company initiating a Phase III trial for their monoclonal antibody, LY-CoV555, for the prevention of COVID-19 in nursing home residents; Arafa Salam, PhD, Infectious Diseases Analyst at GlobalData, a leading data and analytics company offers her view: “Although the use of mobile research facilities for clinical trials may […]
Read more

COVID-19 pandemic severely impacting US reversible contraceptive devices market with 28.9% lost revenue expected in 2020, says GlobalData

Nearly 30% of revenue from reversible contraceptive devices in the US will be lost in 2020 due to COVID-19, as many procedures have been postponed and clinics have been closed. In comparison, developing countries are expected to experience a less severe decline, as governments have previously dealt with providing reproductive health during pandemics such as […]
Read more

July auto sales in Turkey impressive but sustainability remains a question, says GlobalData

Following the news that automotive sales in Turkey grew by 387.5% year-on-year in July 2020, according to Automotive Distributors Association Animesh Kumar, Director of Automotive Consulting at GlobalData, a leading research and consulting company, offers his view: “The surge in sales is impressive but not unbelievable in light of Turkey’s effective response to the COVID-19 […]
Read more
1 … 41 42 43 44 45 … 77